Search | Clinical Trials Finder

Conditions: Coronary Artery Disease
Interventions: Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT; Combination Product
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: East Syracuse, New York • New York, New York • Anderson, South Carolina + 1 more

Conditions: Atrial Fibrillation
Interventions: Not listed
Lead sponsor: Anthos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 9
States / cities: Fullerton, California • Boca Raton, Florida • Homestead, Florida + 6 more

Conditions: Atrial Fibrillation (AF), VTE
Interventions: PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management; Other
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Hartford, Connecticut • Evanston, Illinois • Boston, Massachusetts + 3 more

Conditions: Coronary Artery Lesions
Interventions: XIENCE, DAPT; Device · Drug
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,047 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 101
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 88 more

Conditions: Coronary Artery Disease
Interventions: 3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System; Drug · Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 2,009 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 89
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more

Conditions: Atrial Fibrillation, Atrial Arrhythmia
Interventions: Data collection; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 10
States / cities: Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 4 more

Conditions: Bleeding Complications
Interventions: Clopidogrel, Prasugrel, Tricagrelor; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Immune Thrombocytopenic Purpura
Interventions: rituxan; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 1 Year to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Vahalla, New York

Conditions: Hematuria, Urothelial Carcinoma
Interventions: Cxbladder; Diagnostic Test
Lead sponsor: Pacific Edge Limited; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: San Diego, California • Bay Pines, Florida • Miami, Florida + 7 more

Conditions: Motor Delay, Premature Birth, Intraventricular Hemorrhage, Hypoxic-Ischemic Encephalopathy, Bronchopulmonary Dysplasia
Interventions: Physical Therapy intervention; Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 33 Weeks to 48 Weeks
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Post Partum Haemorrhage, Maternal Care Patterns, High Risk Pregnancy
Interventions: Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding; Device
Lead sponsor: Baymatob Operations Pty Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Denver, Colorado • Baton Rouge, Louisiana • New York, New York + 2 more

Conditions: Infant Development, Infant,Premature, Hydrocephalus, Neonatal Encephalopathy, Infarction, PVL, Thrombosis, Intraventricular Hemorrhage
Interventions: pacifier-activated device; Device
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 32 Weeks to 12 Months
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Blood Loss, Surgical, Blood Loss, Postoperative, Uterine Atony
Interventions: Calcium Gluconate, Saline; Drug · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Bleeding, Thrombosis
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: High Risk Postpartum Hemorrhage (PPH)
Interventions: ROTEM - rotation thromboelastometry testing; Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Coronary Artery Disease, Atherosclerosis, Stent Placement
Interventions: Dual Antiplatelet (DAPT) Therapy, The Synergy® stent; Drug · Device
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 75 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Scottsdale, Arizona • Boston, Massachusetts • New York, New York

Conditions: Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions: XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor); Device · Drug
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 54
States / cities: Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more

Conditions: Bloodloss, Surgical Procedures, Operative
Interventions: Ecallantide, Cyklokapron(R); Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 85 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hemoptysis
Interventions: Not listed
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: C.Surgical Procedure; Cardiac
Interventions: Acute normovolemic hemodilution, Standard care; Procedure
Lead sponsor: Università Vita-Salute San Raffaele; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Charlottesville, Virginia

Conditions: Curvature of Spine
Interventions: Tranexamic Acid; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Perioperative Bleeding
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Postpartum Hemorrhage, Postpartum Depression, Postpartum Sepsis, Postpartum Preeclampsia, Patient Empowerment, Patient Education, Postpartum Care
Interventions: Video Education; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Coronary Syndrome, High Bleeding Risk
Interventions: BioFreedom™ Drug Coated Coronary Stent System, Antiplatelet Drug; Device · Drug
Lead sponsor: Biosensors Europe SA; Industry
Eligibility: Not listed
Enrollment: 1,203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 39
States / cities: Huntsville, Alabama • Hot Springs, Arkansas • La Jolla, California + 34 more

Search by objective public record fields.

A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)

Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke

Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.

EVOLVE Short DAPT Study

Studying Heart Ablation After Left Atrial Closure in High-Bleeding-Risk Atrial Fibrillation Patients

Clopidogrel Monotherapy in Patients With High Bleeding Risk

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

Efficacy and Utility of Cxbladder Tests in Hematuria Patients

Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit

Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage

Pacifier Activated Device and Mother's Voice in Infants at High-risk for Cerebral Palsy

Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony

Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery

ROTEM® Obstetric Hemorrhage Pilot Study

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

XIENCE 28 USA Study

Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery

Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy

Acute Normovolemic Hemodilution in High Risk Cardiac Surgery Patients.

The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery

Platelet Function Testing Help and Intraoperative Bleeding Risk for Patients Who Are on Plavix Prior to Surgery

Postpartum Video Education in High Risk Populations

LEADERS FREE II: BioFreedom™ Pivotal Study